These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3119213)

  • 1. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
    Nakajima H; Izumi Y; Sugihara S; Satoh Y; Isumi S; Gotoh T; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(3):201-8. PubMed ID: 3119213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
    Yoshioka T; Fujiwara H; Takai Y; Ogata M; Shimizu J; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF).
    De Groot JW; De Weger RA; Vandebriel RJ; Den Otter W
    Immunobiology; 1989 Jun; 179(2-3):131-44. PubMed ID: 2676851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
    Yoshioka T; Sato S; Ogata M; Sakamoto K; Sano H; Shima J; Yamamoto H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 enhancement of lymphokine secretion by T lymphocytes: analysis of established clones and primary limiting dilution microcultures.
    Kelso A; MacDonald HR; Smith KA; Cerottini JC; Brunner KT
    J Immunol; 1984 Jun; 132(6):2932-8. PubMed ID: 6233365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
    Sakamoto K; Yoshioka T; Shimizu J; Sato S; Nakajima H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positively selected Lyt-2+ and Lyt-2- mouse T lymphocytes are comparable, after Con A stimulation, in release of IL 2 and of lymphokines acting on B cells, macrophages, and mast cells, but differ in interferon production.
    Guerne PA; Piguet PF; Vassalli P
    J Immunol; 1983 May; 130(5):2225-30. PubMed ID: 6187845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor.
    Svedersky LP; Benton CV; Berger WH; Rinderknecht E; Harkins RN; Palladino MA
    J Exp Med; 1984 Mar; 159(3):812-27. PubMed ID: 6421982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
    Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
    J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage activation factor from EL-4, a murine T-cell line: antigenic characterization by hamster monoclonal antibodies to murine interferon-gamma.
    Meltzer MS; Gilbreath MJ; Crawford RM; Schreiber RD; Nacy CA
    Cell Immunol; 1987 Jul; 107(2):340-7. PubMed ID: 3109744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
    Suzuki R; Suzuki S; Ebina N; Kumagai K
    J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
    Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
    Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antitumor effect of PSK (2): effector mechanism of the antimetastatic effect in the "double grafted tumor system"].
    Ebina T; Kohya H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1847-53. PubMed ID: 3592718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and biochemical characterization of macrophage activating factor (MAF) in murine lymphocytes: physiocochemical similarity of MAF to gamma interferon (IFN-gamma).
    Fukazawa Y; Kagaya K; Miura H; Shinoda T; Natori K; Yamazaki S
    Microbiol Immunol; 1984; 28(6):691-702. PubMed ID: 6434908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.
    Celada A; Gray PW; Rinderknecht E; Schreiber RD
    J Exp Med; 1984 Jul; 160(1):55-74. PubMed ID: 6330272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.